Top in endocrinology: FDA OKs vibration belt for osteopenia; reassuring findings on GLP-1s
The FDA cleared a wearable vibration belt to treat postmenopausal women with osteopenia, according to an industry press release.
The Osteoboost vibration belt (Bone Health Technologies) is indicated to slow the loss of bone strength and density.
“Although lifestyle interventions such as exercise and diet are beneficial to bone, the effect is small,” Laura Bilek, PhD, associate dean for research and associate professor at the University of Nebraska, said in the press release. “The Osteoboost shows promise in slowing the loss of bone density and strength and may fill the treatment gap.”
It was the top story in endocrinology last week.
In another top story, researchers saw no increased short-term risk for pancreatic cancer in adults with type 2 diabetes using GLP-1 receptor agonists.
“Our findings provide additional reassurance to physicians prescribing GLP-1 receptor agonists to patients,” Rachel Dankner, MD, MPH, senior researcher in the Gertner Institute for Epidemiology and Health Policy Research at Sheba Medical Center in Israel, told Healio.
Read these and more top stories in endocrinology below:
FDA clears wearable vibration belt for postmenopausal women with osteopenia
The FDA cleared a wearable vibration belt device as a nonpharmacologic treatment for postmenopausal women with osteopenia, according to an industry press release. Read more.
GLP-1s may not raise short-term pancreatic cancer risk for adults with type 2 diabetes
Adults with type 2 diabetes who use GLP-1 receptor agonists do not have an increased short-term risk for pancreatic cancer, according to findings published in JAMA Network Open. Read more.
‘Everything is negotiable’: How to approach employment contracts
Jonathan D. Leffert, MD, talks with Armand Krikorian, MD, MBA, FACP, FACE, about why health care providers need to consider all the features of an employment contract, from salary and performance expectations to benefits. Read more.
FDA adds boxed warning of increased severe hypocalcemia risk for denosumab
The FDA has added a boxed warning for denosumab to advise patients with advanced chronic kidney disease of an increased risk for severe hypocalcemia, according to an FDA drug safety communication. Read more.
Maternal diabetes increases children’s risk for congenital heart defects
Mothers with type 1 or type 2 diabetes have increased risks for having children with a congenital heart defect, according to a study published in JAMA Network Open. Read more.